AI-generated summary
The authors studied bright light therapy added to ongoing medication in 31 outpatients with difficult-to-treat depression, both unipolar and bipolar, in an open-label trial. They report a statistically significant reduction in depression ratings from the first week, good tolerability, and a response in 9 of 25 patients at follow-up. The authors state that these preliminary results need confirmation in larger placebo-controlled, randomized, double-blind trials.
- Participants
- 31
- Who or what was studied
- Outpatients with difficult-to-treat depression, 16 unipolar and 15 bipolar, of whom 25 completed treatment and follow-up
- Limits stated in the abstract
- The study was open-label with no placebo control, included a small sample, and the authors describe the results as preliminary.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on dovepress.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Depression, Bright light therapy, Light-emitting diode, Placebo-controlled, Open-label study. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.